Key result
A combination of minimally-invasive diagnostic tools based on imaging techniques and specific plasma biomarkers is suggested for early recognition of human diabetic cardiomyopathy.
Why the study?
What are the optimal diagnostic approaches for early detection of diabetic cardiomyopathy?
What are the optimal diagnostic approaches for early detection of diabetic cardiomyopathy?
Advanced imaging modalities combined with specific plasma biomarkers may improve the early diagnosis and stratification of diabetic cardiomyopathy before overt heart failure develops.
Answers are grounded in this paper and cite their sources.
May support earlier diabetic cardiomyopathy detection; leaves open need for prospective validation before clinical adoption.
Diabetic cardiomyopathy (DCM) is a cardiac dysfunction which affects approximately 12% of diabetic patients, leading to overt heart failure and death. However, there is not an efficient and specific methodology for DCM diagnosis, possibly because molecular mechanisms are not fully elucidated, and it remains asymptomatic for many years. Also, DCM frequently coexists with other comorbidities such as hypertension, obesity, dyslipidemia, and vasculopathies. Thus, human DCM is not specifically identified after heart failure is established. In this sense, echocardiography has been traditionally considered the gold standard imaging test to evaluate the presence of cardiac dysfunction, although other techniques may cover earlier DCM detection by quantification of altered myocardial metabolism and strain. In this sense, Phase-Magnetic Resonance Imaging and 2D/3D-Speckle Tracking Echocardiography may potentially diagnose and stratify diabetic patients. Additionally, this information could be completed with a quantification of specific plasma biomarkers related to related to initial stages of the disease. Cardiotrophin-1, activin A, insulin-like growth factor binding protein-7 (IGFBP-7) and Heart fatty-acid binding protein have demonstrated a stable positive correlation with cardiac hypertrophy, contractibility and steatosis responses. Thus, we suggest a combination of minimally-invasive diagnosis tools for human DCM recognition based on imaging techniques and measurements of related plasma biomarkers.
No takes yet. Share an insight, caveat, or question.
Lorenzo-Almorós et al. (2017) conducted a review in Diabetic cardiomyopathy. Diagnostic imaging and biomarkers was evaluated. A combination of minimally-invasive diagnostic tools based on imaging techniques and specific plasma biomarkers is suggested for early recognition of human diabetic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: